半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Galectin 3 (GAL3) ,etc. by FLIA (Flow Luminescence Immunoassay)
LGALS3; CBP35; GALBP; GALIG; MAC2; 35 kDa lectin; Carbohydrate-binding protein 35; Galactose-specific lectin 3; Galactoside-binding protein; Laminin-binding protein; Lectin L-29
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)LMA303Mu
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.98-1000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.327 pg/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2427 ¥ 2521 ¥ 2661 ¥ 2847 ¥ 3034 ¥ 3314 ¥ 3734 ¥ 4668 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 90-101 | 94 |
| EDTA plasma(n=5) | 86-94 | 90 |
| heparin plasma(n=5) | 81-96 | 87 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-102% | 89-101% | 98-105% | 97-105% |
| EDTA plasma(n=5) | 82-93% | 93-101% | 79-101% | 95-102% |
| heparin plasma(n=5) | 98-105% | 87-96% | 78-98% | 83-97% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測(cè)溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA303Mu01 | 半乳糖凝集素3(GAL3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA303Mu01 | 半乳糖凝集素3(GAL3)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA303Mu02 | 半乳糖凝集素3(GAL3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA303Mu02 | 半乳糖凝集素3(GAL3)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA303Mu01 | 半乳糖凝集素3(GAL3)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA303Mu71 | 半乳糖凝集素3(GAL3)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAA303Mu81 | 半乳糖凝集素3(GAL3)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| SEA303Mu | 半乳糖凝集素3(GAL3)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA303Mu | 半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Clinica Chimica Acta | Galectin-1 and galectin-3: plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population [Pubmed:25578395] |
| Scientific Reports | Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension [PubMed: 25747153] |
| Int J Mol Sci | The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension [PubMed: 25984599] |
| Scientifi Reportcs | Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices [PubMed: 26582585] |
| Clin Chim Acta | Galectin-1 and galectin-4: Plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population [PubMed: 25578396] |
| JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION | Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. [pubmed:28431936] |
| 昆明醫(yī)科大學(xué)學(xué)報(bào) | 半乳糖凝集素3 在COPD 和肺癌中的表達(dá)及其意義. [2095610X] |
| Archives of Medical Science | Can we define migraine patients with blood high-sensitivity C-reactive protein and galectin-3 levels in the emergency department? [publication:305625095] |
| Biosensors & Bioelectronics | A sensitive sandwich-type immunosensor for the detection of galectin-3 based on N-GNRs-Fe-MOFs@AuNPs nanocomposites and a novel AuPt-methylene blue nanorod. [pubmed:29096363] |
| Scientific Reports | The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction. [pubmed:28827564] |
| Clinica Chimica Acta | Galectin-3 in patients with coronary heart disease and atrial fibrillation [Pubmed:29287900] |
| Advances in Experimental?Medicine?and?Biology | Molecules of Damage-Associated Patterns in Bronchoalveolar Lavage Fluid and Serum in Chronic Obstructive Pulmonary Disease [Pubmed:29429028] |
| FASEB?Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure [Pubmed: 30230922] |
| american journal of physiology-heart and circulatory physiology | Macrophage galectin-3 enhances intimal translocation of vascular calcification in diabetes mellitus [Pubmed: 32216615] |
| Cardiology | Galectin-3 Induces Atrial Fibrosis by Activating the TGF-β1/Smad Pathway in Patients with Atrial Fibrillation [Pubmed: 32516780] |
| AUSTRALIAN DENTAL JOURNAL | The effect of initial periodontal treatment on gingival crevicular fluid galectin?\3 levels in participants with periodontal disease [33378559] |
| Cell Death & Disease | Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis [33771973] |
| Int J Clin Pract | Serum Galectin?\3 Levels in Patients with Psoriasis [34137138] |
| Phytomedicine | Zerumbone, a humulane sesquiterpene from Syringa pinnatifolia, attenuates cardiac fibrosis by inhibiting of the TGF-β1/Smad signaling pathway after myocardial?… [Pubmed:35405613] |
| Medicine | Regulatory T cells, damage-associated molecular patterns, and myeloid-derived suppressor cells in bronchoalveolar lavage fluid interlinked with chronic obstructive?… [Pubmed:35687771] |
